MLchartDataset catalogue

poziotinib hydrochloride

Term · Oncology and biomedicine · MLC-T-ONC-016195

The hydrochloride salt form of poziotinib, an orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.

Table 1. Record
IdentifierMLC-T-ONC-016195
FieldOncology and biomedicine
SynonymsNOV-1201 hydrochloride; NOV120101 hydrochloride; poziotinib HCl
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016195",
  "term": "poziotinib hydrochloride",
  "field": "Oncology and biomedicine",
  "definition": "The hydrochloride salt form of poziotinib, an orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.",
  "synonyms": [
    "NOV-1201 hydrochloride",
    "NOV120101 hydrochloride",
    "poziotinib HCl"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/poziotinib-hydrochloride/"
}

Record 13,539 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.